Hematology Section, First Department of Propaedeutic Internal Medicine, Laikon Hospital, National and Kapodistrian University of Athens' Medical School, 11527 Athens, Greece.
Immunology Department, Laikon Hospital, 11527 Athens, Greece.
Int J Mol Sci. 2024 Mar 1;25(5):2862. doi: 10.3390/ijms25052862.
The majority of patients with Diffuse Large B-cell Lymphoma (DLBCL) will respond to first-line treatment and be cured. However, the disease is heterogeneous, and biomarkers able to discriminate patients with suboptimal prognosis are needed. M2 CD163-positive tumor-associated macrophages (TAMs) were shown to be implicated in DLBCL disease activity regulation. Serum-soluble CD163 (sCD163) functions as a scavenger receptor for haptoglobin-hemoglobin complexes and is mostly expressed by monocytes and macrophages. Its levels are used to determine macrophage activation. We aimed to determine serum sCD163 in a sample of DLBCL patients and study eventual correlations with parameters of disease activity or survival. Serum sCD163 levels were measured in 40 frozen sera from patients diagnosed with DLBCL and 30 healthy individuals (HIs) using an enzyme-linked immunosorbent assay (ELISA). Statistical analyses were performed using SPSS version 28. The results showed that patients who achieved complete response after standard-of-care immunochemotherapy and were alive and disease-free after 12 months of follow-up but had elevated sCD163 levels (above median) at diagnosis presented a significantly worse overall survival compared to those with initial serum sCD163 levels below the median ( = 0.03). Consequently, serum sCD163 levels in patients with DLBCL may constitute a marker of long-term response to chemoimmunotherapy.
大多数弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者对一线治疗有反应并被治愈。然而，这种疾病具有异质性，需要能够区分预后不佳患者的生物标志物。M2 CD163 阳性肿瘤相关巨噬细胞 (TAMs) 被证明参与 DLBCL 疾病活动的调节。血清可溶性 CD163 (sCD163) 作为结合珠蛋白-血红蛋白复合物的清道夫受体发挥作用，主要由单核细胞和巨噬细胞表达。其水平用于确定巨噬细胞的激活状态。我们旨在确定 DLBCL 患者样本中的血清 sCD163，并研究其与疾病活动或生存的参数之间的潜在相关性。使用酶联免疫吸附测定 (ELISA) 测量了 40 份冷冻的 DLBCL 患者血清和 30 份健康个体 (HI) 血清中的血清 sCD163 水平。使用 SPSS 版本 28 进行统计分析。结果表明，在标准免疫化学治疗后达到完全缓解且在 12 个月随访后存活且无疾病的患者，但在诊断时 sCD163 水平升高（高于中位数），其总体生存明显较差与初始血清 sCD163 水平低于中位数的患者相比 ( = 0.03)。因此，DLBCL 患者的血清 sCD163 水平可能是对化疗免疫治疗的长期反应的标志物。
